Skip to search formSkip to main contentSkip to account menu

c-Met Inhibitor MSC2156119J

Known as: MSC2156119J 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
In clinical practice, acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer… 
2015
2015
Objectives: To evaluate the dose/exposure/target inhibition/tumor growth relationship of MSC2156119J, an orally administered… 
2015
2015
The therapeutic success of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC) is hampered… 
2014
2014
2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary… 
2014
2014
TPS4151 Background: Patients (pts) with HCC have a poor prognosis. Effective treatments are limited, particularly in Asia, which… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Overexpression of the c-Met oncoprotein can… 
2014
2014
ABSTRACT Aim: c-Met overexpression is associated with poor clinical prognosis. This dose-escalation study (3 + 3 design… 
2013
2013
The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls…